BridgeBio Pharma, Inc. Operating Lease, Payments
BridgeBio Pharma, Inc. (BBIO) reported Operating Lease, Payments of $3.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-10
- BridgeBio Pharma, Inc. operating lease, payments for the quarter ending 2026-06-30 was $1.82M, a 10.63% increase year-over-year.
- BridgeBio Pharma, Inc. operating lease, payments for the quarter ending 2026-03-31 was $1.85M, a 25.99% increase year-over-year.
- BridgeBio Pharma, Inc. operating lease, payments for the quarter ending 2025-12-31 was $1.79M, a 182.78% increase year-over-year.
- BridgeBio Pharma, Inc. operating lease, payments for the quarter ending 2025-09-30 was $1.64M, a 10.96% increase year-over-year.
- BridgeBio Pharma, Inc. operating lease, payments for fiscal 2025 was $6.55M, a 28.57% increase from fiscal 2024.
- BridgeBio Pharma, Inc. operating lease, payments for fiscal 2024 was $5.09M, a 5.45% increase from fiscal 2023.
- BridgeBio Pharma, Inc. operating lease, payments for fiscal 2023 was $4.83M, a 22.67% decline from fiscal 2022.
- BridgeBio Pharma, Inc. operating lease, payments for fiscal 2022 was $6.25M, a 2.01% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 3 month as first filed | Operating Lease, Payments 6 month | Operating Lease, Payments 6 month as first filed | Operating Lease, Payments 9 month | Operating Lease, Payments 9 month as first filed | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $3.67M 10-Q · filed 2026-08-10 | $5.46M derived: sum of 3 quarters · filed 2026-08-10 | $7.10M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $1.85M 10-Q · filed 2026-05-07 | $3.64M derived: sum of 2 quarters · filed 2026-05-07 | $5.28M derived: sum of 3 quarters · filed 2026-05-07 | $6.93M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.43M derived: sum of 2 quarters · filed 2026-02-24 | $5.08M derived: sum of 3 quarters · filed 2026-08-10 | $6.55M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $3.29M derived: sum of 2 quarters · filed 2026-08-10 | $4.76M 10-Q · filed 2025-10-29 | $5.39M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $3.12M 10-Q · filed 2026-08-10 | $3.75M derived: sum of 3 quarters · filed 2026-08-10 | $5.23M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $1.47M 10-Q · filed 2026-05-07 | $2.10M derived: sum of 2 quarters · filed 2026-05-07 | $3.58M derived: sum of 3 quarters · filed 2026-05-07 | $4.97M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $633.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.11M derived: sum of 2 quarters · filed 2026-02-24 | $3.50M derived: sum of 3 quarters · filed 2026-02-24 | $5.09M 10-K · filed 2026-02-24 | $5.90M 10-K · filed 2025-02-20 | |||
| 2024-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $2.86M derived: sum of 2 quarters · filed 2025-10-29 | $4.46M 10-Q · filed 2025-10-29 | $5.62M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $2.98M 10-Q · filed 2025-08-05 | $4.14M derived: sum of 3 quarters · filed 2026-02-24 | $5.37M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $1.59M 10-Q · filed 2025-04-29 | $2.75M derived: sum of 2 quarters · filed 2026-02-24 | $3.98M derived: sum of 3 quarters · filed 2026-02-24 | $5.17M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.39M derived: sum of 2 quarters · filed 2026-02-24 | $3.58M derived: sum of 3 quarters · filed 2026-02-24 | $4.83M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.42M derived: sum of 2 quarters · filed 2024-11-12 | $3.67M 10-Q · filed 2024-11-12 | $5.10M derived: sum of 4 quarters · filed 2025-02-20 | ||||
| 2023-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $2.44M 10-Q · filed 2024-08-01 | $3.87M derived: sum of 3 quarters · filed 2025-02-20 | $5.34M derived: sum of 4 quarters · filed 2025-02-20 | ||||
| 2023-03-31 | $1.25M 10-Q · filed 2024-05-02 | $2.68M derived: sum of 2 quarters · filed 2025-02-20 | $4.15M derived: sum of 3 quarters · filed 2025-02-20 | $5.67M derived: sum of 4 quarters · filed 2025-02-20 | ||||
| 2022-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $2.90M derived: sum of 2 quarters · filed 2025-02-20 | $4.42M derived: sum of 3 quarters · filed 2025-02-20 | $6.25M 10-K · filed 2025-02-20 | ||||
| 2022-09-30 | $1.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $3.00M derived: sum of 2 quarters · filed 2023-11-02 | $4.82M 10-Q · filed 2023-11-02 | $6.47M derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2022-06-30 | $1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $3.35M 10-Q · filed 2023-08-03 | $5.00M derived: sum of 3 quarters · filed 2024-02-22 | $6.61M derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2022-03-31 | $1.82M 10-Q · filed 2023-05-04 | $3.47M derived: sum of 2 quarters · filed 2024-02-22 | $5.08M derived: sum of 3 quarters · filed 2024-02-22 | $6.47M derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2021-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $3.26M derived: sum of 2 quarters · filed 2024-02-22 | $4.65M derived: sum of 3 quarters · filed 2024-02-22 | $6.12M 10-K · filed 2024-02-22 | ||||
| 2021-09-30 | $1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $3.00M derived: sum of 2 quarters · filed 2022-11-03 | $4.47M 10-Q · filed 2022-11-03 | $5.89M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.86M 10-Q · filed 2022-08-04 | $4.28M derived: sum of 3 quarters · filed 2023-02-23 | $5.38M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-03-31 | $1.47M 10-Q · filed 2022-05-05 | $2.89M derived: sum of 2 quarters · filed 2023-02-23 | $3.99M derived: sum of 3 quarters · filed 2023-02-23 | $5.69M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2020-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $2.52M derived: sum of 2 quarters · filed 2023-02-23 | $4.22M derived: sum of 3 quarters · filed 2023-02-23 | $4.17M 10-K · filed 2023-02-23 | ||||
| 2020-09-30 | $1.10M 10-Q · filed 2020-11-05 | $2.80M derived: sum of 2 quarters · filed 2020-11-05 | $2.75M 10-Q · filed 2021-11-04 | $2.70M 10-Q · filed 2020-11-05 | ||||
| 2020-06-30 | $1.70M 10-Q · filed 2020-08-11 | $1.68M 10-Q · filed 2021-08-05 | $1.00M 10-Q · filed 2020-08-11 | |||||
| 2020-03-31 | $730.00K 10-Q · filed 2021-05-06 | $700.00K 10-Q · filed 2020-05-14 | ||||||
| 2019-12-31 | $2.00M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |